Active Stocks
Sat Mar 02 2024 12:29:56
  1. Tata Steel share price
  2. 155.30 3.53%
  1. HDFC Bank share price
  2. 1,430.50 -0.05%
  1. State Bank Of India share price
  2. 773.40 0.53%
  1. ICICI Bank share price
  2. 1,084.60 -0.21%
  1. Axis Bank share price
  2. 1,095.00 -0.40%
Business News/ Markets / Mark To Market/  Sun Pharma shares get a boost as its specialty biz delivers the goods

Sun Pharma shares get a boost as its specialty biz delivers the goods

The drugmaker’s margin improvement stood out, despite some rising cost overheads in Q2
  • Sun Pharma also launched 22 products in domestic market, which may reflect in growth henceforth
  • Sun Pharma’s revenues have come ahead of expectations but its margins improvement stands out despite some cost overheads increasing in Q2. Photo: MintPremium
    Sun Pharma’s revenues have come ahead of expectations but its margins improvement stands out despite some cost overheads increasing in Q2. Photo: Mint

    Pharma companies have had momentum on their side since the first quarter, and Sun Pharmaceutical Industries Ltd’s Q2 numbers show the good run is continuing.

    The company’s revenues have come ahead of expectations but its margin improvement stood out despite some cost overheads rising in Q2. The stock’s jump of 3.5% post the results announcement on Tuesday was largely due to the improvement in margin, driven by the specialty products business.

    The pickup in the domestic business is also notable considering that the company has a strong chronic therapies portfolio. Note that chronic therapies have been slow-moving in the domestic market. Domestic revenue growth of about 6% sequentially is notable in that backdrop, and has gone down well with the Street. Sun Pharma also launched about 22 new products in the domestic market, which is likely to reflect in improved revenue growth in coming quarters.

    Booster shot
    View Full Image
    Booster shot

    The rest-of-the-world market has shown high growth as well. Dollar revenues from this segment grew 31% sequentially. Emerging markets’ sequential revenue growth of 21% is quite encouraging as well.

    Active pharma ingredient (API) sales also grew well, given that some stocking was already evident in the last quarter. As a result, overall revenue grew about 5.3%, much ahead of the Street estimates.

    Sun Pharma’s speciality products business has seen an improvement in the US with revenues rising 19% sequentially in US dollars. “Sun Pharma’s specialty business and products like Ilumya and Cequa have reached pre-covid levels. As these products have high margins, the margin improvement story looks set to continue," said Bharat Celly, analyst, Equirus Securities.

    Despite cost increases during the quarter, particularly on operations and research and development, Sun Pharma beat the Street’s estimates quite well. Ebitda (earnings before interest, tax, depreciation and amortization) margins came at 25.6% in Q2, about 130 basis points higher sequentially, and well over last year’s levels.

    Of course, some of the operational expenses are likely to rebound further with the easing of lockdowns. Sun is also likely to increase its field force as well.

    Nevertheless, revenue growth in the US should remain good on the back of its speciality product pipeline. The price erosion seen in the generic space over the past few years in the US market is slowing.

    The company is increasing filings in the US market. The firm has about 20 tentative approvals, while it received four approvals for drug launches last quarter.

    While the stock is up about 7% over its pre-covid highs, valuations look fair at 21 times FY22 consensus earnings. Even so, an earnings upgrade cannot be ruled out on the back of improving margin profile.

    Unlock a world of Benefits! From insightful newsletters to real-time stock tracking, breaking news and a personalized newsfeed – it's all here, just a click away! Login Now!

    Catch all the Business News, Market News, Breaking News Events and Latest News Updates on Live Mint. Check all the latest action on Budget 2024 here. Download The Mint News App to get Daily Market Updates.
    More Less
    Published: 03 Nov 2020, 07:06 PM IST
    Next Story footLogo
    Recommended For You

    Get the best recommendations on Stocks, Mutual Funds and more based on your Risk profile!

    Let’s get started
    Switch to the Mint app for fast and personalized news - Get App

    Chat with MintGenie